Release
📈 Stocks
CSL Partners With Alentis in $1.55 Billion Rare Disease Drug Deal
(1 hour ago)
CSL secures global rights to Alentis Therapeutics' lixudebart in a deal worth up to US$1.55 billion, marking a major expansion of its…